Italia markets close in 8 hours 25 minutes

Becton, Dickinson and Company (BDX)

NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
237,72+1,01 (+0,43%)
Alla chiusura: 04:00PM EDT
237,72 0,00 (0,00%)
Dopo ore: 06:00PM EDT

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417-1880
United States
201 847 6800
https://www.bd.com

Settore/iHealthcare
SettoreMedical Instruments & Supplies
Impiegati a tempo pieno73.000

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Thomas E. Polen Jr.President, CEO & Chairman3,46MN/D1973
Mr. Christopher J. DelOreficeExecutive VP & CFO1,6MN/D1972
Ms. Shana Carol NealExecutive VP & Chief People Officer1,79MN/D1966
Mr. David B. HickeyExecutive VP & President of Life Sciences Segment1,11M562,03k1964
Mr. Michael GarrisonExecutive VP & President of Medical segment1,73MN/D1970
Mr. Thomas J. SpoerelSenior VP, Controller & Chief Accounting OfficerN/DN/D1979
Ms. Elizabeth McCombsExecutive VP & Chief Technology OfficerN/DN/D1976
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.Senior VP, Chief Scientific Officer & Co-Chair of Scientific Advisory BoardN/DN/DN/D
Ms. Denise Russell FlemingExecutive VP of Technology & Global Services and Chief Information OfficerN/DN/D1970
Mr. Greg RodetisHead of Investor RelationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Becton, Dickinson and Company al 1 marzo 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 10; diritti degli azionisti: 10; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.